KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Bristol Myers Squibb's Accounts Payables fell 74.96% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 billion, marking a year-over-year decrease of 74.96%. This contributed to the annual value of $3.6 billion for FY2025, which is 74.96% down from last year.
  • As of Q4 2025, Bristol Myers Squibb's Accounts Payables stood at $3.6 billion, which was down 74.96% from $4.3 billion recorded in Q3 2025.
  • Over the past 5 years, Bristol Myers Squibb's Accounts Payables peaked at $5.4 billion during Q2 2025, and registered a low of $2.6 billion during Q3 2022.
  • In the last 5 years, Bristol Myers Squibb's Accounts Payables had a median value of $3.2 billion in 2023 and averaged $3.4 billion.
  • As far as peak fluctuations go, Bristol Myers Squibb's Accounts Payables tumbled by 2014.41% in 2022, and later surged by 4468.14% in 2025.
  • Bristol Myers Squibb's Accounts Payables (Quarter) stood at $2.9 billion in 2021, then increased by 3.09% to $3.0 billion in 2022, then rose by 7.2% to $3.3 billion in 2023, then rose by 10.52% to $3.6 billion in 2024, then fell by 0.75% to $3.6 billion in 2025.
  • Its Accounts Payables was $3.6 billion in Q4 2025, compared to $4.3 billion in Q3 2025 and $5.4 billion in Q2 2025.